Recent updates on pharmacologic therapy in nonalcoholic fatty liver disease

키워드

참고문헌 (23)

1. Harrison SA, "Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH : Results from randomized phase III STELLAR trials", J Hepatol, 73, pp.26~39 (2020)
2. Anstee QM, "Cenicriviroc lacked efficacy to treat liver fibrosis in nonalcoholic steatohepatitis : AURORA Phase III Randomized Study", Clin Gastroenterol Hepatol (2023)[DOI]
3. Younossi ZM, "Obeticholic acid for the treatment of nonalcoholic steatohepatitis : interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial", Lancet, 394, pp.2184~2196 (2019)
4. Sanyal AJ, "Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of precirrhotic fibrosis due to non-alcoholic steatohepatitis", J Hepatol (2023)[DOI]
5. Harrison SA, "Resmetirom(MGL-3196)for the treatment of non-alcoholic steatohepatitis : a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial", Lancet, 394, pp.2012~2024 (2019)
6. Harrison S, "Primary results from MAESTRO-NASH a pivotal phase 352-week serial liver biopsy study in 966 patients with NASH and fibrosis", J Hepatol, 78, pp.S1~ (2023)
7. Newsome PN, "A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis", N Engl J Med, 384, pp.1113~1124 (2021)
8. Loomba R, "Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis : a randomised, placebo-controlled phase 2 trial", Lancet Gastroenterol Hepatol, 8, pp.511~522 (2023)
9. Chalasani N, "Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension", Gastroenterology, 158, pp.1334~1345 (2020)
10. Jastreboff AM, "Tirzepatide once weekly for the treatment of obesity", N Engl J Med, 387, pp.205~216 (2022)
11. Gastaldelli A, "Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes(SURPASS-3 MRI) : a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial", Lancet Diabetes Endocrinol, 10, pp.393~406 (2022)
12. Robertson D, "PROXYMO demonstrates safety and efficacy of cotadutide, a novel incretin co-agonist in biopsy-proven non-cirrhotic NASH with fibrosis. Oral abstract", Hepatology, 74, pp.1383A~ (2021)
13. Choi J, "Therapeutic effect of a novel long-acting GLP-1", GIP, Diabetes, pp.2020, 69(Suppl 1)[DOI]
14. Abdelmalek M, "HM15211, a novel GLP-1", GIP, 2a, multi-center, randomized, placebo-controlled trial, pp.J Hepatol, 2020[DOI]
15. Tilg H, "NASH drug treatment development : challenges and lessons", Lancet Gastroenterol Hepatol, 8, pp.943~954 (2023)
16. Sun L, "Effects of dapagliflozin in patients with nonalcoholic fatty liver disease : A systematic review and meta-analysis of randomized controlled trials", Clin Res Hepatol Gastroenterol, 46, pp.101876~ (2022)
17. Shimizu M, "Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease", Diabetes Obes Metab, 21, pp.285~292 (2019)
18. Ratziu V, "Aramchol in patients with nonalcoholic steatohepatitis : a randomized, double-blind, placebo-controlled phase 2b trial", Nat Med, 27, pp.1825~1835 (2021)
19. Francque SM, "A randomized, controlled trial of the Pan-PPAR agonist lanifibranor in NASH", N Engl J Med, 385, pp.1547~1558 (2021)
20. Loomba R, "Pegbelfermin in patients with nonalcoholic steatohepatitis and stage 3 fibrosis (FALCON 1): A randomized phase 2b study", Clin Gastroenterol Hepatol (2023)[DOI]
21. Abdelmalek MF, "Pegbelfermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis (FALCON 2): A randomized phase 2b study", Clin Gastroenterol Hepatol (2023)[DOI]
22. Loomba R, "Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH", N Engl J Med, 389, pp.998~1008 (2023)
23. An J, "Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials", Clin Mol Hepatol, 29(Suppl), pp.S268~S275 (2023)

관련 논문AI추천